Cargando…

Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy

Cyclic di-nucleotides (CDNs) are widespread second messenger signalling molecules that regulate fundamental biological processes across the tree of life. These molecules are also potent modulators of the immune system, inducing a Type I interferon response upon binding to the eukaryotic receptor STI...

Descripción completa

Detalles Bibliográficos
Autor principal: Waters, Christopher M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670957/
https://www.ncbi.nlm.nih.gov/pubmed/34905701
http://dx.doi.org/10.1098/rsob.210277
_version_ 1784615065272451072
author Waters, Christopher M.
author_facet Waters, Christopher M.
author_sort Waters, Christopher M.
collection PubMed
description Cyclic di-nucleotides (CDNs) are widespread second messenger signalling molecules that regulate fundamental biological processes across the tree of life. These molecules are also potent modulators of the immune system, inducing a Type I interferon response upon binding to the eukaryotic receptor STING. Such a response in tumours induces potent immune anti-cancer responses and thus CDNs are being developed as a novel cancer immunotherapy. In this review, I will highlight the use, challenges and advantages of using naturally occurring CDNs to treat cancer.
format Online
Article
Text
id pubmed-8670957
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Royal Society
record_format MEDLINE/PubMed
spelling pubmed-86709572021-12-28 Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy Waters, Christopher M. Open Biol Review Cyclic di-nucleotides (CDNs) are widespread second messenger signalling molecules that regulate fundamental biological processes across the tree of life. These molecules are also potent modulators of the immune system, inducing a Type I interferon response upon binding to the eukaryotic receptor STING. Such a response in tumours induces potent immune anti-cancer responses and thus CDNs are being developed as a novel cancer immunotherapy. In this review, I will highlight the use, challenges and advantages of using naturally occurring CDNs to treat cancer. The Royal Society 2021-12-15 /pmc/articles/PMC8670957/ /pubmed/34905701 http://dx.doi.org/10.1098/rsob.210277 Text en © 2021 The Authors. https://creativecommons.org/licenses/by/4.0/Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, provided the original author and source are credited.
spellingShingle Review
Waters, Christopher M.
Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
title Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
title_full Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
title_fullStr Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
title_full_unstemmed Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
title_short Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
title_sort au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670957/
https://www.ncbi.nlm.nih.gov/pubmed/34905701
http://dx.doi.org/10.1098/rsob.210277
work_keys_str_mv AT waterschristopherm aunaturaleuseofbiologicallyderivedcyclicdinucleotidesforcancerimmunotherapy